US008987339B2

(12) **United States Patent**
Askari et al.

(10) **Patent No.: US 8,987,339 B2**
(45) **Date of Patent: Mar. 24, 2015**

(54) **SOLID POLYGLYCOL-BASED BIOCOMPATIBLE PRE-FORMULATION**

(71) Applicant: **Medicus Biosciences LLC**, San Jose, CA (US)

(72) Inventors: **Syed H. Askari**, San Jose, CA (US); **Yeon S. Choi**, Emeryville, CA (US)

(73) Assignee: **Medicus Biosciences LLC**, San Jose, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/212,457**

(22) Filed: **Mar. 14, 2014**

(65) **Prior Publication Data**

US 2014/0271528 A1 Sep. 18, 2014

Related U.S. Application Data

(60) Provisional application No. 61/785,477, filed on Mar. 14, 2013.

(51) **Int. Cl.**

A61L 27/18	(2006.01)
A61L 27/52	(2006.01)
A61L 26/00	(2006.01)
A61K 9/00	(2006.01)
A61L 27/36	(2006.01)
A61K 47/00	(2006.01)
A61K 31/00	(2006.01)
A61K 31/728	(2006.01)
A61K 45/06	(2006.01)
A61K 31/155	(2006.01)
A61K 31/505	(2006.01)
A61K 31/573	(2006.01)
A61K 31/635	(2006.01)
A61K 33/00	(2006.01)
A61K 35/28	(2006.01)

(52) **U.S. Cl.**

CPC ***A61L 26/0019*** (2013.01); ***A61L 27/18*** (2013.01); ***A61L 27/52*** (2013.01); ***A61L 26/008*** (2013.01); ***A61K 9/0024*** (2013.01); *A61K 35/28* (2013.01); ***A61L 27/3604*** (2013.01); ***A61L 27/3695*** (2013.01); *A61L 2400/06* (2013.01); *A61L 2430/34* (2013.01); ***A61K 47/00*** (2013.01); ***A61K 31/00*** (2013.01); ***A61K 31/728*** (2013.01); ***A61K 45/06*** (2013.01); ***A61K 31/155*** (2013.01); ***A61K 31/505*** (2013.01); ***A61K 31/573*** (2013.01); ***A61K 31/635*** (2013.01); ***A61K 33/00*** (2013.01)

USPC **514/772.3**; 524/879; 424/78.06; 424/78.36

(58) **Field of Classification Search**

USPC 514/772.3; 524/879

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,037,384	A	8/1991	Chang	
5,336,175	A	8/1994	Mames	
5,858,345	A	1/1999	Charles et al.	
5,874,500	A	2/1999	Rhee et al.	
6,051,648	A	4/2000	Rhee et al.	
6,135,118	A	10/2000	Dailey	
6,149,931	A	11/2000	Schwartz et al.	
6,153,211	A	11/2000	Hubbell et al.	
6,180,687	B1	1/2001	Hammer et al.	
6,207,772	B1	3/2001	Hatsuda et al.	
6,312,725	B1	11/2001	Wallace et al.	
6,458,889	B1	10/2002	Trollsas et al.	
6,475,508	B1	11/2002	Schwartz et al.	
6,547,714	B1	4/2003	Dailey	
6,566,406	B1	5/2003	Pathak et al.	
6,605,294	B2	8/2003	Sawhney	
6,624,245	B2	9/2003	Wallace et al.	
6,632,457	B1	10/2003	Sawhney	
6,703,037	B1	3/2004	Hubbell et al.	
6,703,378	B1	3/2004	Kunzler et al.	
6,818,018	B1	11/2004	Sawhney et al.	
7,009,343	B2	3/2006	Lim et al.	
7,255,874	B1	8/2007	Bobo et al.	
7,332,566	B2	2/2008	Pathak et al.	
7,553,810	B2	6/2009	Gong et al.	
7,592,418	B2	9/2009	Pathak et al.	
8,388,995	B1 *	3/2013	Ali et al.	424/429

(Continued)

FOREIGN PATENT DOCUMENTS

WO	WO-97-22371	6/1997
WO	WO-99-03454	1/1999

(Continued)

OTHER PUBLICATIONS

3M Company, 3M™ Vetbond™ Veterinary Tissue Adhesive, Material Safety Data Sheet, Jun. 1, 2009.

Abbott Animal Health, GLUture®, Information Brochure, Feb. 2009.

Baino, "Towards an ideal biomaterial for vitreous replacement: Historical overview and future trends," Acta Biomaterialia 7: 921-935 (2011).

Brandi et al., "Biodegradable hydrogels for time-controlled release of tethered peptides or proteins," Biomacromolecules 11: 496-504 (2010).

Campbell et al., "Evaluation of the PleuraSeal™ Lung Sealant System as a Thoracic Sealant in a Canine Lung Resection Model," Covidien (2007).

(Continued)

Primary Examiner — Anoop Singh
Assistant Examiner — Anna Falkowitz
(74) *Attorney, Agent, or Firm* — Wilson Sonsini Goodrich & Rosati

(57) **ABSTRACT**

Provided herein are pre-formulations forming a biocompatible hydrogel polymer comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally a therapeutic agent and/or viscosity enhancer. In some embodiments, the biocompatible hydrogel polymer covers a wound in a mammal and adheres to the surrounding skin tissue. In other embodiments, the hydrogel polymer is delivered into a joint space to treat joint disease or navicular disease.

16 Claims, 24 Drawing Sheets